Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors

Exclusion Criteria

• •1. Patients receiving chemotherapy or other investigational drugs must be discontinued 14 days prior to enrollment.
• •2. Cardiac disease: Congestive heart failure \> class II NYHA. Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.
• •3. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.
• •4. Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management.
• •5. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
• •6. Active clinically serious infection \> CTCAE Grade 2